Purpose: The importance of endometrial maturation at estimated time of implantation for the outcome of lVF treatment in regularly menstruating
INTRODUCTION
The pregnancy rate in in vitro fertilization (IVF) is now 30-40% at most centers, and even if this is an improvement, attempts are being made to increase the implantation rate further. One possible cause for low implantation rate is suboptimal endometrial quality. During the normal menstrual cycle, the endometrium undergoes hormone-dependent proliferation and secretory differentiation in preparation for implantation.
Histologic procedures have been developed for characterization and evaluation of endometrial maturation in relation to circulating steroid hormone levels during the luteal phase of the menstrual cycle. The method of choice for estimation of endometrial quality is still that of Noyes et al. (I) . Retarded endometrial development in the luteal phase has been suggested as a cause of implantation failure, and the prevalence among infertile women varies widely, from 12.4 to 65.3% (2) (3) (4) (5) . The incidence ofendometrial retardation among fertile controls was less than 5% (6) . This great variation in infertile women might, however, be due partly to inaccurate precision of histologic dating (7, 8) .
The aim of the present study was to evaluate the importance of endometrial maturation at estimated time of implantation for the outcome of IVF treatment in regularly menstruating women with tubal infertility.
MATERIALS AND METHODS
or delivery 1 year before admission to the study. For clinical characteristics see Table I .
Follicle Size and Endometrial Thickness Measurements
To determine the size of the dominant follicle, see on which day the follicle disappears, and measure the thickness of the endometrium, ultrasonographic investigations were performed transvaginally using a Siemens Sonoline SI/200 real-time scanner, equipped with a mechanical sector rotating 5-6-7.5-MHz transducer. All ultrasound measurements were made by the same person.
Study group
Forty-three women awaiting IVF treatment, who had failed to conceive for at least 2 years following tubal reconstructive surgery, volunteered for the study. All women were regularly menstruating and underwent, before surgery, a complete investigation for infertility including basal body temperature, characterization of the menstrual cycle by repeated serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone (P4) in the luteal phase. All fulfilled our standard criteria for normal ovulatory cycles (9) . All men had normal spermiograms on at least two occasions according to the World Health Organization (I 0) criteria. For clinical characteristics see Table I .
Control Group
During the same period, 30 apparently healthy women, with a history of regular periods and with proven fertility, volunteered for the study. None of them had used steroidal contraceptives or an intrauterine device during the previous 3 months. None had a history of pelvic inflammatory disease or an abortion 
Study Plan
Blood samples were obtained from all subjects in a randomly selected cycle by venepuncture in the morning between 0730 and 0830. Five milliliters of blood was drawn each time into test tubes, then centrifuged within 30 rain, and the serum was frozen and stored at -20°C until assayed. Blood was collected on days, 3, 10-15, and 19-26. On days 10-15 urine samples were collected to estimate the day of the LH peak, using a self-test (OvuQvick; Monoclonal Antibodies Inc., Sunnyvale, CA). The LH peak was also determined in serum samples. E2 and P4 were measured during the luteal phase, on cycle days 19-26. E2, e4, FSH, and LH measurements were performed with an Immulite system, DPC, LA, and chemiluminescence. E2 and P4 were analyzed with a competitive immunoassay. FSH and LH were analyzed with a noncompetitive immunoassay. Limits of determination were as follows: E2, 73-7340 pM; P4, 0.64-127 nM; FSH, 0.1-170 IU/L; and LH, 0.7-200 IUFL. Precision (within run) was as follows: E2, 6.3-15%; P4, 6.9-13%; FSH, 5.4-7.7%; and LH, 4.8-6.5%.
In the luteal phase P4 and E2 concentrations were expressed as areas under the curve (AUC), which were calculated as sums of partial areas obtained according to the following formula In the same menstrual cycle, endometrial biopsies were obtained from the anterior wall of the uterine cavity using a Randall curette (Stille Werner AB, Stockholm, Sweden) without cervical dilatation or anesthesia. The criteria of Noyes etal. (1) were used for the histologic dating. The day of biopsy was grouped in relation to the LH peak and varied from LH + 3 to LH + 6. Endometrium out of phase was defined as histologic dating differing by more than 2 days from that in relation to the LH peak.
The specimens were fixed immediately in Bouin's solution for light microscopic examination after paraffin embedding and hematoxylin-eosin staining. Ten arbitrarily chosen microscopic fields were analyzed in each biopsy specimen. (Zeiss light microscope, × 10, wide-angle eyepieces with micrometer disk, objective ×40; Carl Zeiss, Germany). In each microscopic field the following six indices were assessed: (i) number of transversely sectioned glands (expressed as glands per microscopic field), (ii) number of glandular mitoses (expressed as mitoses per 1000 glandular cells), (iii) number of stromal mitoses (expressed as mitoses per 1000 stromal cells), (iv) diameter (l~m) of the glandular lumen in the transversely sectioned glands, (v) height (ixm) of the glandular epithelium, and (vi) number of glandular cells with basal or'subnuclear vacuolation (expressed as basal vacuolated cells per 1000 glandular cells). The morphological evaluation of the endometrial biopsies was performed blindly by one of the authors as described previously (11).
IVF Treatment Protocol
All patients followed our standard long gonadotropin releasing hormone agonist (GnRHa) and human menopausal gonadotropin (hMG) protocol for stimulation as described (12) . GnRHa (Suprefact; Svenska Hoechst AB, Stockholm, Sweden) was administered as a nasal spray, 6 X 200 I~g daily, starting on day 21 of the menstrual cycle. After down-regulation was verified by ultrasound examination, hMG (Pergonal; Serono Nordic AB, Sollentuna, Sweden) was administered i.m., 150--225 IU daily. Follicular development was monitored by vaginal ultrasound measurements of follicles and endometrium using a Siemens Sonoline SI/200 combined with blood samples for Ez analysis. The day for ovum pickup was determined when the leading follicle reached a diameter of 17 mm and the serum levels of Ez reached at least 2500 pM. Then 5000 IU human chorionic gonadotropin (hCG; Profasi; Serono Nordic AB) was given i.m. Approximately 35 hr later, ovum pickup was performed by transvaginal ultrasound-guided follicle aspiration. Gamete and preembryo handling as well as embryo replacement has been described previously (12) . Luteal-phase support was given using 5000 IE hCG i.m., at 3, 6, and 9 days after embryo replacement. During the study period, treatment was restricted to three cycles (two women in the nonpregnant group had four cycle starts but only three treatment cycles) and the number of replaced preembryos was limited to three.
Statistical Methods
Results are presented as means __. SD, medians, and ranges (Table IV) except where indicated otherwise. Statistical evaluation was performed using ANOVA, Student's t test, and Fishers' exact test whenever appropriate. Comparison of the hormonal characteristics between the groups was performed by using MannWhitney two-tailed test. For statistical evaluation of the morphometric indices related to the midcycle LH surge, ANOVA was used. P values < 0.05 were considered significant.
Ethical Aspects
The study was approved by the Ethics Committee of the Karolinska Hospital.
RESULTS
Clinical characteristics of the study group and the controls are presented in Table I . Certain characteristics of the infertile women with respect to outcome of IVF treatment are shown in Table II . Those women who became pregnant had significantly fewer treatment cycles (P < 0.001) and needed fewer ampoules of gonadotropins (P < 0.001). They also had fewer oocyte retrievals (P < 0.001) and more oocytes per retrieval (P < 0.001), a higher fertilization rate (P < 0.01), and more replaced preembryos per replacement (P < 0.01) compared with nonpregnant women.
Six infertile women and two controls (Table III) did have mid-and late-proliferative endometrium in the luteal phase on cycle days LH + 3 to LH + 6. One infertile woman and one control did present with excellent ovarian function (low FSH and high E2 and P4 AUC, subject no. I-2 and C-I) (13) . The others exhibited impaired ovarian function as indicated by the high basic FSH and low P4 AUC in the luteal phase. These eight women were excluded from further analyses. Table IV shows E2 and P4 AUC in the luteal phase in 37 infertile women and 28 controls in relation to endometrial maturation. Normal controls did not differ from the infertile women who became pregnant. The endometrial dating resulted in significantly more cases of retarded endometrial development (n = 12) in the infertile women who did not become pregnant compared to those who became pregnant (r = 3) (P < 0.01). A comparison of six morphological characteristics of the endometrium in 37 women before IVF treatment and 28 controls is shown in Table V . The biopsies Mann-Whitney test: *P < 0.05; **P < 0.01. were taken on cycle days LH +3 and +4 and days LH +5 and +6. The pregnant women in the infertile group did not differ from the controls. The numbers of glandular mitoses and stromal mitoses were significantly higher in those women who did not become pregnant (P < 0.01) compared with those who became pregnant, independent of the cycle days. The endometrial biopsies obtained on cycle days LH + 5 and LH + 6 showed significant differences in glandular epithelial height (P < 0.01) and number of vacuolated cells among the nonpregnant (P < 0.01), the pregnant (P < 0.05), and the control women.
DISCUSSION
In our study delayed endometrial maturation in the luteal phase was more common in women who did not become pregnant after IVF, compared both to controis and to those women who became pregnant, indicating that the endometrium in l~his population was significant for implantation. Six infertile women and two controls presented with mid-and late-proliferative endometrium in the luteal phase on cycle days LH + 3 to LH + 6, in the presence of E2 and P4 secretion (11) . Our observation of two fertile control women having proliferative endometrium in the luteal phase indicates that fertile women accidentally may have serious endometrial disturbances. Our findings are in agreement with Li et al. (5) , who found normal 1'4 levels in at least 20% of infertile women in combination with proliferative endometrium and suggested end organ insensitivity as explanation in these cases. In another study, Li et al. (14) showed some morphological similarities in the endometrium between women with unexplained infertility and fertile women treated with P4 receptor antagonist, which strongly supports this theory.
The importance of endometrial adequacy for implantation of the preembryo and establishment and maintenance of pregnancy is still a matter of discussion. Satisfactory endometrial development depends on normal amounts of the steroid hormones E2 and P4 produced by the ovary (15) (16) (17) . There have been many attempts to determine the serum P4 levels that will indicate normal endometrial development during the luteal phase. Israel et al. (18) reported that a midluteal serum P4 of 10 nM or higher was indicative of ovulation and of the maturation of a normal secretory endometrium. Several other investigators confirmed correlation between endometrial morphology and the presence of P4 secretion in the luteal phase (7, 19, 20) .
The steroid hormones mediate their effects on the target tissue, the endometrium, via cytosolic receptors. Adequacy of the luteal phase can therefore be assessed only by both multiple P4 determinations and endometrial biopsies (3, 21, 22) .
Data available from oocyte donation programs suggest that the postmenopausal endometrium maintains its ability to respond to exogenous steroids and that it has the capacity to develop into a receptive endometrium for preembryo implantation and gestation (23) (24) (25) (26) . Embryo quality is known to be a major contributor to the failure or the success of IVF treatment and the age of the women donating oocytes has been shown to have higher significance for the outcome of treatment than the age of the recipient (27, 28) . Moreover, the women who did not become pregnant in our study presented with lower P4 and Ez secretion in the luteal phase compared with pregnant women, which could obviously not be overcome by ovarian stimulation and luteal-phase support. This finding indicates that ovarian function may be more important for the outcome of IVF treatment than endometrial maturation.
In conclusion, we found a higher frequency of retarded endometrial development in women who did not become pregnant following IVF treatment. However this may be a secondary effect due to impaired ovarian function in these women, as judged from the significantly lower E2 and P4. In some cases, endometrial insensitivity might be involved in retarded endometrial development and failure of implantation after IVF treatment. However, our results do not allow conclusions concerning the relative importance of the endometrium compared to preembryo quality (29) (30) (31) . This is a matter that has to be investigated further.
